Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34312214.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1593 and PMC identifier 8738124.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action-based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial design options in this area, review examples from the literature and their unique immunologic aspects, and highlight how these trials have been underutilized. We illustrate how new technologies and translationally focused approaches can be successfully used to develop different classes of immunotherapeutic agents.
Medical subject headings
- Immunotherapy
- Neoplasms